Published in PLoS One on October 25, 2011
Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55
The impact of differential antiviral immunity in children and adults. Nat Rev Immunol (2012) 1.21
Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol (2012) 1.05
The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01
HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. PLoS One (2012) 0.99
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol (2014) 0.97
The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol (2013) 0.94
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev (2014) 0.91
Toll-like receptor 9 in breast cancer. Front Immunol (2014) 0.89
Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World J Gastroenterol (2012) 0.88
MyD88 and its divergent toll in carcinogenesis. Trends Immunol (2013) 0.88
Merkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus. Cancers (Basel) (2014) 0.87
Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell Mol Immunol (2014) 0.87
Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer. Oncol Lett (2013) 0.86
Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol (2015) 0.83
Downregulation of Toll-Like Receptor 9 Expression by Beta Human Papillomavirus 38 and Implications for Cell Cycle Control. J Virol (2015) 0.82
Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. PLoS One (2016) 0.80
RNA-seq analysis reveals significant transcriptome changes in turbot (Scophthalmus maximus) suffering severe enteromyxosis. BMC Genomics (2014) 0.80
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol (2014) 0.79
TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expression. Oncogenesis (2016) 0.78
Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore) (2016) 0.77
Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular Carcinoma. Front Chem (2016) 0.77
Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response. Int J Cancer (2014) 0.76
UV Radiation Activates Toll-like Receptor 9 Expression in Primary Human Keratinocytes, an Event Inhibited by Human Papillomavirus Type 38 E6 and E7 Oncoproteins. J Virol (2017) 0.75
Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget (2016) 0.75
Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection. PLoS One (2016) 0.75
Innate immune targets of hepatitis B virus infection. World J Hepatol (2016) 0.75
Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel) (2017) 0.75
Toll like receptor7 polymorphisms in relation to disease susceptibility and progression in Chinese patients with chronic HBV infection. Sci Rep (2017) 0.75
Opiate use inhibits TLR9 signaling pathway in vivo: possible role in pathogenesis of HIV-1 infection. Sci Rep (2017) 0.75
Activation of STING in hepatocytes suppresses the replication of hepatitis B virus. Antimicrob Agents Chemother (2017) 0.75
TLR9 gene polymorphism -1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population. J Cancer Res Clin Oncol (2017) 0.75
Triggering the interferon antiviral response through an IKK-related pathway. Science (2003) 11.62
Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol (2005) 9.70
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Type I interferons in host defense. Immunity (2006) 7.32
Viral hepatitis B. Lancet (2003) 4.86
Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A (2002) 4.52
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol (1988) 3.21
The Toll receptor family and microbial recognition. Trends Microbiol (2000) 3.01
Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol (2005) 2.95
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
The immune response during hepatitis B virus infection. J Gen Virol (2006) 2.21
HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2007) 2.01
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A (1998) 1.81
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol (2005) 1.64
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology (2008) 1.57
Plasmacytoid dendritic cells--virus experts of innate immunity. Semin Immunol (2005) 1.52
Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology (2004) 1.46
The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol (2010) 1.44
Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol (2006) 1.35
Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog (2010) 1.33
Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology (2005) 1.33
HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol (2009) 1.31
Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol (2010) 1.25
Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract (2010) 1.20
Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol (2002) 1.17
Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol (2004) 1.17
Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology (2006) 1.15
Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect (2009) 1.07
EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol (2010) 1.03
Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol (2007) 0.97
Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. J Biol Chem (1999) 0.96
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology (2006) 0.95
Silencing of natural interferon producing cell activation by porcine circovirus type 2 DNA. Immunology (2006) 0.95
Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann N Y Acad Sci (2003) 0.88
Expression of toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads. J Huazhong Univ Sci Technolog Med Sci (2009) 0.86
Expression of hepatitis B surface antigen major subtypes in Pichia pastoris and purification for in vitro diagnosis. Protein Expr Purif (2007) 0.83
Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection. J Viral Hepat (2007) 0.82
Receptors and ligands involved in viral induction of type I interferon production by plasmacytoid dendritic cells. Immunobiology (2006) 0.82
Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B. APMIS (2005) 0.78
Toxoplasma gondii: localization of purine nucleoside phosphorylase activity in vitro and in vivo by electron microscopy. Med Mol Morphol (2005) 0.77
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol (2002) 4.22
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res (2006) 4.00
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol (2002) 3.20
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology (2009) 3.16
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology (2009) 2.48
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett (2006) 2.37
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res (2005) 2.24
Genetics of lung-cancer susceptibility. Lancet Oncol (2010) 2.24
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer (2006) 2.17
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Molecular identification and characterization of two proposed new enterovirus serotypes, EV74 and EV75. J Gen Virol (2004) 2.02
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat (2002) 1.99
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology (2002) 1.94
On the origin of G --> T transversions in lung cancer. Mutat Res (2003) 1.89
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest (2010) 1.88
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol (2003) 1.87
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol (2011) 1.85
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol (2009) 1.82
The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol (2003) 1.81
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Hepatitis B virus genetic variability and evolution. Virus Res (2007) 1.80
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS (2005) 1.80
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology (2005) 1.80
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS (2006) 1.76
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. Gut (2010) 1.71
Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: epidemiologic and biomolecular study. J Gastroenterol Hepatol (2006) 1.70
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol (2011) 1.70
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology (2004) 1.69
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2009) 1.63
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol (2008) 1.63
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology (2013) 1.62
Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett (2011) 1.62
Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol (2006) 1.61
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol (2010) 1.57
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother (2011) 1.51
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology (2011) 1.49
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene (2005) 1.49
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Biospecimen reporting for improved study quality (BRISQ). J Proteome Res (2011) 1.48
Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis (2007) 1.47
Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev (2006) 1.47
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology (2010) 1.47
Massively regulated genes: the example of TP53. J Pathol (2010) 1.46
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett (2008) 1.44
In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology (2009) 1.43
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res (2007) 1.41
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS (2008) 1.40
Hepatitis C screening practices among private practitioners: impact of an information campaign. Gastroenterol Clin Biol (2005) 1.40
[Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients]. Gastroenterol Clin Biol (2003) 1.40